Document Format Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
1 | REGISTRATION STATEMENT | ff12018_aptorumgroup.htm | F-1 | 4189784 |
2 | SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF APTORUM GR | ff12018ex3-1_aptorum.htm | EX-3.1 | 645750 |
3 | SPECIMEN ORDINARY SHARE CERTIFICATE | ff12018ex4-1_aptorum.htm | EX-4.1 | 8301 |
4 | FORM OF SERIES A CONVERTIBLE PROMISSORY NOTE | ff12018ex4-2_aptorum.htm | EX-4.2 | 156568 |
5 | APPOINTMENT LETTER BETWEEN THE COMPANY AND IAN HUEN (FOUNDER, CHIEF EXECUTIVE OF | ff12018ex10-1_aptorum.htm | EX-10.1 | 91481 |
6 | EMPLOYMENT LETTER BETWEEN THE COMPANY AND SABRINA KHAN (CHIEF FINANCIAL OFFICER) | ff12018ex10-2_aptorum.htm | EX-10.2 | 67982 |
7 | ADDENDUM TO EMPLOYMENT LETTER BETWEEN COMPANY AND SABRINA KHAN (CHIEF FINANCIAL | ff12018ex10-3_aptorum.htm | EX-10.3 | 10415 |
8 | APPOINTMENT LETTER BETWEEN THE COMPANY AND DARREN LUI (CHIEF BUSINESS OFFICER, P | ff12018ex10-4_aptorum.htm | EX-10.4 | 73567 |
9 | EMPLOYMENT LETTER BETWEEN THE COMPANY AND CLARK CHENG (CHIEF MEDICAL OFFICER & D | ff12018ex10-5_aptorum.htm | EX-10.5 | 52962 |
10 | ADDENDUM TO APPOINTMENT LETTER BETWEEN THE COMPANY AND CLARK CHENG (CHIEF MEDICA | ff12018ex10-6_aptorum.htm | EX-10.6 | 73658 |
11 | SECOND ADDENDUM TO APPOINTMENT LETTER BETWEEN THE COMPANY AND CLARK CHENG (CHIEF | ff12018ex10-7_aptorum.htm | EX-10.7 | 20893 |
12 | THIRD ADDENDUM TO APPOINTMENT LETTER BETWEEN THE COMPANY AND CLARK CHENG (CHIEF | ff12018ex10-8_aptorum.htm | EX-10.8 | 6407 |
13 | APPOINTMENT LETTER BETWEEN THE COMPANY AND KEITH CHAN (CHIEF SCIENTIFIC OFFICER) | ff12018ex10-9_aptorum.htm | EX-10.9 | 26439 |
14 | APPOINTMENT LETTER BETWEEN THE COMPANY AND CHARLES BATHURST (INDEPENDENT NON-EXE | ff12018ex10-10_aptorum.htm | EX-10.10 | 51644 |
15 | APPOINTMENT LETTER BETWEEN THE COMPANY AND MIRKO SCHERER (INDEPENDENT NON-EXECUT | ff12018ex10-11_aptorum.htm | EX-10.11 | 80741 |
16 | EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND JUSTIN WU (INDEPENDENT NON-EXECUTIV | ff12018ex10-12_aptorum.htm | EX-10.12 | 89866 |
17 | EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND DOUGLAS ARNER (INDEPENDENT NON-EXEC | ff12018ex10-13_aptorum.htm | EX-10.13 | 81235 |
18 | MANAGEMENT AGREEMENT BETWEEN THE COMPANY AND GUARDIAN CAPITAL MANAGEMENT LIMITED | ff12018ex10-14_aptorum.htm | EX-10.14 | 194075 |
19 | CONSULTING AGREEMENT BETWEEN THE COMPANY AND GLOBOASIA, LLC (INCLUDES PROVISIONS | ff12018ex10-15_aptorum.htm | EX-10.15 | 47545 |
20 | MANAGEMENT AGREEMENT BETWEEN THE COMPANY AND APTUS CAPITAL LIMITED, DATED OCTOBE | ff12018ex10-16_aptorum.htm | EX-10.16 | 171541 |
21 | FIRST ADDENDUM TO THE MANAGEMENT AGREEMENT BETWEEN THE COMPANY AND APTUS CAPITAL | ff12018ex10-17_aptorum.htm | EX-10.17 | 22397 |
22 | SECOND ADDENDUM TO THE MANAGEMENT AGREEMENT BETWEEN THE COMPANY AND APTUS CAPITA | ff12018ex10-18_aptorum.htm | EX-10.18 | 15363 |
23 | SUBSCRIPTION AGREEMENT BETWEEN THE COMPANY AND PEACE RANGE LIMITED, DATED APRIL | ff12018ex10-19_aptorum.htm | EX-10.19 | 654425 |
24 | SHARE CHARGE AGREEMENT BETWEEN THE COMPANY, JURCHEN INVESTMENT CORPORATION AND P | ff12018ex10-20_aptorum.htm | EX-10.20 | 531774 |
25 | DEED OF GUARANTEE OF JURCHEN INVESTMENT CORPORATION, ACKNOWLEDGED BY PEACE RANGE | ff12018ex10-21_aptorum.htm | EX-10.21 | 93861 |
26 | CHARGE ACCOUNT AGREEMENT BETWEEN THE COMPANY AND PEACE RANGE LIMITED, DATED APRI | ff12018ex10-22_aptorum.htm | EX-10.22 | 412398 |
27 | BOND CERTIFICATE BETWEEN THE COMPANY AND PEACE RANGE LIMITED, DATED APRIL 25, 20 | ff12018ex10-23_aptorum.htm | EX-10.23 | 519057 |
28 | ESCROW AGREEMENT BETWEEN THE COMPANY AND PEACE RANGE LIMITED, DATED APRIL 25, 20 | ff12018ex10-24_aptorum.htm | EX-10.24 | 168716 |
29 | 2017 SHARE OPTION PLAN | ff12018ex10-25_aptorum.htm | EX-10.25 | 98200 |
30 | FORM OF SECURITIES PURCHASE AGREEMENT FOR THE SERIES A CONVERTIBLE PROMISSORY NO | ff12018ex10-26_aptorum.htm | EX-10.26 | 145211 |
31 | LOCK-UP AGREEMENT FOR SERIES A CONVERTIBLE PROMISSORY NOTES, DATED MAY 15, 2018 | ff12018ex10-27_aptorum.htm | EX-10.27 | 7635 |
32 | EXCLUSIVE LICENSE AGREEMENT FOR NLS-1 DATED JULY 3, 2017 | ff12018ex10-28_aptorum.htm | EX-10.28 | 297614 |
33 | ADDENDUM TO LICENSE AGREEMENT FOR NLS-1 DATED FEBRUARY 9, 2018 | ff12018ex10-29_aptorum.htm | EX-10.29 | 35922 |
34 | EXCLUSIVE PATENT LICENSE AGREEMENT FOR ALS-1 | ff12018ex10-30_aptorum.htm | EX-10.30 | 225580 |
35 | FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT FOR ALS-1 DATED JUNE 7 | ff12018ex10-31_aptorum.htm | EX-10.31 | 14000 |
36 | EXCLUSIVE PATENT LICENSE AGREEMENT FOR ALS-4 | ff12018ex10-32_aptorum.htm | EX-10.32 | 214184 |
37 | FIRST AMENDMENT TO THE EXCLUSIVE PATENT LICENSE AGREEMENT DATED JUNE 7, 2018 | ff12018ex10-33_aptorum.htm | EX-10.33 | 19275 |
38 | SUB-TENANCY AGREEMENT FOR GUANGDONG INVESTMENT TOWER | ff12018ex10-34_aptorum.htm | EX-10.34 | 137621 |
39 | SERVICE AGREEMENT BETWEEN COVAR PHARMACEUTICALS INCORPORATED AND VIDENS INCORPOR | ff12018ex10-35_aptorum.htm | EX-10.35 | 112669 |
40 | APPOINTMENT LETTER AND ADDENDUM TO SERVICE AGREEMENT WITH COVAR PHARMACEUTICALS | ff12018ex10-36_aptorum.htm | EX-10.36 | 179177 |
41 | APPOINTMENT LETTER AND ADDENDUM TO SERVICE AGREEMENT WITH COVAR PHARMACEUTICALS | ff12018ex10-37_aptorum.htm | EX-10.37 | 187320 |
42 | CODE OF BUSINESS CONDUCT AND ETHICS OF THE COMPANY | ff12018ex14-1_aptorum.htm | EX-14.1 | 92761 |
43 | LIST OF SUBSIDIARIES | ff12018ex21-1_aptorum.htm | EX-21.1 | 5822 |
44 | CONSENT OF MARCUM BERNSTEIN & PINCHUK LLP | ff12018ex23-1_aptorum.htm | EX-23.1 | 4087 |
45 | CHARTER OF THE AUDIT COMMITTEE | ff12018ex99-1_aptorum.htm | EX-99.1 | 70539 |
46 | CHARTER OF THE COMPENSATION COMMITTEE | ff12018ex99-2_aptorum.htm | EX-99.2 | 35591 |
47 | CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE | ff12018ex99-3_aptorum.htm | EX-99.3 | 28817 |
48 | GRAPHIC | img_001.jpg | GRAPHIC | 3262 |
49 | GRAPHIC | img_002.jpg | GRAPHIC | 9935 |
50 | GRAPHIC | img_003.jpg | GRAPHIC | 178723 |
51 | GRAPHIC | img_004.jpg | GRAPHIC | 320867 |
52 | GRAPHIC | img_005.jpg | GRAPHIC | 716269 |
53 | GRAPHIC | img_006.jpg | GRAPHIC | 153181 |
54 | GRAPHIC | img_007.jpg | GRAPHIC | 15691 |
55 | GRAPHIC | img_008.jpg | GRAPHIC | 6673 |
56 | GRAPHIC | img_009.jpg | GRAPHIC | 22240 |
57 | GRAPHIC | img_010.jpg | GRAPHIC | 39669 |
58 | GRAPHIC | img_011.jpg | GRAPHIC | 452841 |
59 | GRAPHIC | img_012.jpg | GRAPHIC | 71308 |
60 | GRAPHIC | img_013.jpg | GRAPHIC | 169774 |
61 | GRAPHIC | img_014.jpg | GRAPHIC | 47242 |
62 | GRAPHIC | img_015.jpg | GRAPHIC | 9601 |
63 | GRAPHIC | img_016.jpg | GRAPHIC | 3460 |
64 | GRAPHIC | img_017.jpg | GRAPHIC | 3363 |
65 | GRAPHIC | img_018.jpg | GRAPHIC | 3872 |
66 | GRAPHIC | logo.jpg | GRAPHIC | 11831 |
67 | GRAPHIC | image_002.jpg | GRAPHIC | 1916 |
68 | GRAPHIC | ex3-1_001.jpg | GRAPHIC | 4041 |
69 | GRAPHIC | ex10-1_001.jpg | GRAPHIC | 1192 |
70 | GRAPHIC | ex10-2_001.jpg | GRAPHIC | 1192 |
71 | GRAPHIC | ex10-3_001.jpg | GRAPHIC | 1192 |
72 | GRAPHIC | ex10-4_001.jpg | GRAPHIC | 1192 |
73 | GRAPHIC | ex10-5_001.jpg | GRAPHIC | 1192 |
74 | GRAPHIC | ex10-6_001.jpg | GRAPHIC | 1192 |
75 | GRAPHIC | ex10-7_001.jpg | GRAPHIC | 1192 |
76 | GRAPHIC | ex10-8_001.jpg | GRAPHIC | 1192 |
77 | GRAPHIC | ex10-9_001.jpg | GRAPHIC | 1192 |
78 | GRAPHIC | ex10-10_001.jpg | GRAPHIC | 1192 |
79 | GRAPHIC | ex10-11_001.jpg | GRAPHIC | 1192 |
80 | GRAPHIC | ex10-12_001.jpg | GRAPHIC | 1192 |
81 | GRAPHIC | ex10-14_001.jpg | GRAPHIC | 1192 |
82 | GRAPHIC | ex10-18_001.jpg | GRAPHIC | 8056 |
83 | GRAPHIC | ex10-19_001.jpg | GRAPHIC | 8056 |
84 | GRAPHIC | ex10-19_002.jpg | GRAPHIC | 3084 |
85 | GRAPHIC | ex10-21_001.jpg | GRAPHIC | 8056 |
86 | GRAPHIC | ex10-20_001.jpg | GRAPHIC | 5539 |
87 | GRAPHIC | ex10-36_01.jpg | GRAPHIC | 1192 |
88 | GRAPHIC | ex10-37_01.jpg | GRAPHIC | 1192 |
89 | GRAPHIC | ex10-8_1.jpg | GRAPHIC | 1192 |
Complete submission text file | 0001213900-18-012108.txt | 13640817 |
IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: F-1 | Act: 33 | File No.: 333-227198 | Film No.: 181054755
SIC: 2834 Pharmaceutical Preparations